Table 2.
Response to Induction Chemotherapy by Assigned Treatment Group
| Response | Treatment Arm |
|||||
|---|---|---|---|---|---|---|
| DNR |
MXR |
IDA |
||||
| No. | % | No. | % | No. | % | |
| No. of patients | 721 | 719 | 717 | |||
| Overall complete response | 495 | 68.7 | 502 | 69.8 | 480 | 66.9 |
| Partial response | 16 | 2.2 | 14 | 1.9 | 21 | 2.9 |
| Resistant disease | 98 | 13.6 | 83 | 11.5 | 102 | 14.2 |
| Persistent hypoplasia | 5 | 0.7 | 7 | 1.0 | 3 | 0.4 |
| Early death* | 23 | 3.2 | 21 | 2.9 | 24 | 3.3 |
| Death in hypoplasia | 64 | 8.9 | 72 | 10.0 | 74 | 10.3 |
| Unknown/missing data | 20 | 2.8 | 20 | 2.8 | 13 | 1.8 |
Abbreviations: DNR, daunorubicin; MXR, mitoxantrone; IDA, idarubicin.
*
Early death was defined as death before the completion of the first cycle of induction therapy, and death in hypoplasia was defined as death after the completion of the induction cycle (1 or 2) before hematologic recovery.